Home/Pipeline/Biosimilar Pipeline (Confidential)

Biosimilar Pipeline (Confidential)

Oncology, Autoimmune Diseases

DevelopmentActive

Key Facts

Indication

Oncology, Autoimmune Diseases

Phase

Development

Status

Active

Company

Gland Pharma

About Gland Pharma

Founded in 1978, Gland Pharma has grown into one of the world's largest injectable-focused companies, renowned for its high-quality manufacturing and extensive product portfolio. The company is majority-owned by Shanghai Fosun Pharmaceutical and has a significant presence in the US market through its subsidiary in Princeton, New Jersey. Its strategic focus includes expanding its CDMO services, developing complex injectable products, and leveraging its expertise in biologics and sterile injectables to drive growth in key therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Critical Care Anti-infectives Cardiovascular Central Nervous System Gastrointestinal Hematology

Other Oncology, Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Biosimilars Pipeline	Laurus Labs	Development	Active
Novel Monoclonal Antibodies	Changchun High-Tech Industry	Pre-clinical	Research
Biosimilar (Rituximab)	Ipca Laboratories	Development	Active
Biosimilar Candidates	China Resources Pharmaceutical Group	Phase 3	Active
Biosimilars (e.g., trastuzumab, rituximab)	Aspen Pharmacare	Approved	Commercial